NO20041503L - Pyrimidinoner som melanin konsentrerende hormon reseptor 1 - Google Patents

Pyrimidinoner som melanin konsentrerende hormon reseptor 1

Info

Publication number
NO20041503L
NO20041503L NO20041503A NO20041503A NO20041503L NO 20041503 L NO20041503 L NO 20041503L NO 20041503 A NO20041503 A NO 20041503A NO 20041503 A NO20041503 A NO 20041503A NO 20041503 L NO20041503 L NO 20041503L
Authority
NO
Norway
Prior art keywords
pyrimidinones
hormone receptor
concentrating hormone
melanin concentrating
melanin
Prior art date
Application number
NO20041503A
Other languages
English (en)
Norwegian (no)
Inventor
Anthony Louis Handlon
Andrew J Carpenter
Joel P Cooper
Donald L Hertzog
Yu C Guo
Jason D Speake
David Richard Witty
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20041503L publication Critical patent/NO20041503L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/10Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D257/12Six-membered rings having four nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20041503A 2001-10-15 2004-04-13 Pyrimidinoner som melanin konsentrerende hormon reseptor 1 NO20041503L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124627.1A GB0124627D0 (en) 2001-10-15 2001-10-15 Novel compounds
PCT/US2002/032739 WO2003033476A1 (en) 2001-10-15 2002-10-15 Pyrimidinones as melanin concentrating hormone receptor 1

Publications (1)

Publication Number Publication Date
NO20041503L true NO20041503L (no) 2004-05-13

Family

ID=9923785

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20041503A NO20041503L (no) 2001-10-15 2004-04-13 Pyrimidinoner som melanin konsentrerende hormon reseptor 1
NO20041504A NO20041504L (no) 2001-10-15 2004-04-13 Lactamderivater som antagonister for humane 11CBY reseptorer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20041504A NO20041504L (no) 2001-10-15 2004-04-13 Lactamderivater som antagonister for humane 11CBY reseptorer.

Country Status (21)

Country Link
EP (2) EP1442025B1 (cg-RX-API-DMAC7.html)
JP (2) JP2005508966A (cg-RX-API-DMAC7.html)
KR (2) KR20050043724A (cg-RX-API-DMAC7.html)
CN (2) CN1596247A (cg-RX-API-DMAC7.html)
AT (2) ATE356119T1 (cg-RX-API-DMAC7.html)
BR (2) BR0213242A (cg-RX-API-DMAC7.html)
CA (2) CA2463509A1 (cg-RX-API-DMAC7.html)
CO (2) CO5580779A2 (cg-RX-API-DMAC7.html)
CZ (2) CZ2004499A3 (cg-RX-API-DMAC7.html)
DE (2) DE60218721T2 (cg-RX-API-DMAC7.html)
ES (2) ES2279009T3 (cg-RX-API-DMAC7.html)
GB (1) GB0124627D0 (cg-RX-API-DMAC7.html)
HU (2) HUP0402346A2 (cg-RX-API-DMAC7.html)
IL (2) IL161074A0 (cg-RX-API-DMAC7.html)
MX (2) MXPA04003534A (cg-RX-API-DMAC7.html)
NO (2) NO20041503L (cg-RX-API-DMAC7.html)
NZ (1) NZ531911A (cg-RX-API-DMAC7.html)
PL (2) PL370138A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004110053A (cg-RX-API-DMAC7.html)
WO (2) WO2003033480A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA200402672B (cg-RX-API-DMAC7.html)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446286T1 (de) 2001-11-26 2009-11-15 Schering Corp Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1618112A1 (en) * 2003-04-11 2006-01-25 SmithKline Beecham Corporation Heterocyclic mchr1 antagonists
AU2004265189B2 (en) * 2003-08-15 2010-03-04 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives
KR100747042B1 (ko) * 2003-08-19 2007-08-07 솔젠트 (주) 신물질6-메틸-3-펜에틸-3,4-디히드로-1h-큐나졸린-2-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물
AU2004285913A1 (en) * 2003-10-23 2005-05-12 Glaxo Group Limited 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2555824C (en) * 2004-02-13 2011-06-07 Banyu Pharmaceutical Co., Ltd. Fused-ring 4-oxopyrimidine derivative
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
MX2007007227A (es) * 2004-12-17 2007-08-21 Lilly Co Eli Derivados de tiazolopiridinona como antagonistas del receptor mch.
WO2006085692A1 (ja) * 2005-02-14 2006-08-17 Banyu Pharmaceutical Co., Ltd 4(3h)-キナゾリノン誘導体の結晶
US7989445B2 (en) 2005-04-28 2011-08-02 Takeda Pharmaceutical Company Limited Thienopyrimidone compound
WO2007011286A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
RU2008112221A (ru) * 2005-08-31 2009-10-10 Селджин Корпорейшн (Us) Соединения ряда изоиндолимидов, их композиции и способы применения
PT1939204E (pt) * 2005-10-19 2013-03-14 Kissei Pharmaceutical Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
AR056155A1 (es) * 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
EP1966164B1 (en) 2005-12-21 2013-03-06 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EP1987042B1 (en) * 2006-02-15 2015-01-21 Sanofi Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
CA2636605A1 (en) 2006-02-15 2007-08-23 Lothar Schwink Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
MY149854A (en) 2006-02-15 2013-10-31 Sanofi Aventis Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
JP5175228B2 (ja) 2006-02-15 2013-04-03 サノフイ 新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
WO2007142217A1 (ja) * 2006-06-07 2007-12-13 Banyu Pharmaceutical Co., Ltd. 1-フェニルピリドン誘導体
US8263772B2 (en) 2006-06-08 2012-09-11 Eli Lilly And Company MCH receptor antagonists
CN101460503A (zh) 2006-06-08 2009-06-17 伊莱利利公司 新的mch受体拮抗剂
MX2009001043A (es) 2006-08-08 2009-02-06 Sanofi Aventis Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
EP2121703A4 (en) 2006-08-18 2011-12-28 Astrazeneca Ab THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
ES2483866T3 (es) 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
JP5269804B2 (ja) * 2006-12-14 2013-08-21 イーライ リリー アンド カンパニー 新規なmch受容体拮抗薬
MX2009007337A (es) 2007-01-10 2009-07-15 Albany Molecular Res Inc Indazoles sustituidos con 5-piridinona.
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DE102007028925A1 (de) 2007-06-22 2008-12-24 Saltigo Gmbh Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ, インコーポレイテッド 5−ピリジノン置換インダゾール
JP5632612B2 (ja) * 2007-12-05 2014-11-26 あすか製薬株式会社 ラクタム化合物又はその塩及びppar活性化剤
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012036233A1 (ja) * 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101236188B1 (ko) * 2011-03-10 2013-02-22 한국화학연구원 신규한 피롤로피리디논 유도체 및 그의 mch 수용체-1 관련 질환에 대한 치료학적 용도
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
NO3175985T3 (cg-RX-API-DMAC7.html) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2747810T3 (es) 2014-06-05 2020-03-11 Bayer Cropscience Ag Compuestos bicíclicos como agentes para combatir parásitos
BR112018012914B1 (pt) 2015-12-22 2023-04-18 SHY Therapeutics LLC Composto, uso de um composto e composição farmacêutica
WO2018029141A1 (de) * 2016-08-12 2018-02-15 Bayer Cropscience Aktiengesellschaft Verfahren zur herstellung von 4-substituierten 2,3-dihydro-1-benzofuranderivaten durch zyklisierung von 2-(2-diazonium-6-substituierten-phenyl)ethanol salzen
EP3509587B1 (en) 2016-09-12 2023-12-06 Valo Health, Inc. Monocyclic compounds useful as gpr120 modulators
JP7065081B2 (ja) * 2016-09-12 2022-05-11 インテグラル ヘルス, インコーポレイテッド Gpr120モジュレーターとして有用な二環式化合物
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AU2018288841B2 (en) 2017-06-21 2022-09-29 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease
WO2019063708A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
TW201922724A (zh) 2017-09-29 2019-06-16 德商拜耳廠股份有限公司 經取代之3-苯基喹唑啉-4(3h)-酮及其用途
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
CN110563730B (zh) * 2019-07-29 2022-03-25 江苏理工学院 高纯度n10-三氟乙酰蝶酸的制备方法
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN113651800B (zh) * 2021-09-07 2022-08-19 山东铂源药业股份有限公司 一种甲磺酸奥希替尼的制备方法
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL137227B2 (en) * 1984-03-28 1986-05-31 Univ Lodzki Process for preparing novel n-/dialkylaminoalkoxyphenyl/-imides of tetrahydrophtalic acids
ES2199366T3 (es) * 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
AU7315700A (en) * 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
MXPA04003532A (es) 2004-07-22
PL370587A1 (en) 2005-05-30
DE60217147T2 (de) 2007-10-31
MXPA04003534A (es) 2004-07-22
ATE349434T1 (de) 2007-01-15
EP1442025A1 (en) 2004-08-04
CO5580778A2 (es) 2005-11-30
CA2463509A1 (en) 2003-04-24
RU2004110053A (ru) 2005-10-20
ATE356119T1 (de) 2007-03-15
CZ2004498A3 (cs) 2004-07-14
IL160872A0 (en) 2004-08-31
IL161074A0 (en) 2004-08-31
DE60218721T2 (de) 2007-11-15
EP1436267B1 (en) 2006-12-27
DE60217147D1 (de) 2007-02-08
HUP0402346A2 (hu) 2005-02-28
ZA200402814B (en) 2005-04-13
NO20041504L (no) 2004-05-13
EP1436267A1 (en) 2004-07-14
WO2003033476A1 (en) 2003-04-24
NZ531911A (en) 2004-11-26
JP2005510487A (ja) 2005-04-21
ES2279009T3 (es) 2007-08-16
CZ2004499A3 (cs) 2004-08-18
KR20040045833A (ko) 2004-06-02
CN1596247A (zh) 2005-03-16
BR0213040A (pt) 2004-10-05
HUP0402335A3 (en) 2006-02-28
PL370138A1 (en) 2005-05-16
CN1571774A (zh) 2005-01-26
ES2283647T3 (es) 2007-11-01
GB0124627D0 (en) 2001-12-05
KR20050043724A (ko) 2005-05-11
BR0213242A (pt) 2004-09-28
DE60218721D1 (en) 2007-04-19
EP1442025B1 (en) 2007-03-07
JP2005508966A (ja) 2005-04-07
CA2463508A1 (en) 2003-04-24
ZA200402672B (en) 2005-04-05
CO5580779A2 (es) 2005-11-30
WO2003033480A1 (en) 2003-04-24
HUP0402335A2 (hu) 2005-02-28

Similar Documents

Publication Publication Date Title
NO20041503L (no) Pyrimidinoner som melanin konsentrerende hormon reseptor 1
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
CY1113054T1 (el) Παραγωγα διαμινης
NO20041493L (no) Kjemiske forbindelser.
DK1392642T3 (da) Hidtil ukendte forbindelser som anti-inflammatoriske, immunmodulatoriske og antiproliferative midler
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
DK1385515T3 (da) Spiropyrazole forbindelser
FI903331A0 (fi) Substituerade kinazolinoner, vilka aer anvaendbara som angiotensin-ii-antagonister.
CY1111759T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη συγκεκριμενων τριαζολοπυριμιδινων ως ρ2τ ανταγωνιστων
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
MXPA03009602A (es) Analogos de nociceptina.
BRPI0516242A (pt) compostos tieno-pirimidina tendo atividade fungicida
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
EA200601030A1 (ru) 7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ
DE60039695D1 (de) Antifucoidan antikörper
DE60211018D1 (de) Fungizide thiazolderivate
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
ECSP003511A (es) Procedimiento para preparar derivados de 10,11-metanobenzosuberano
ECSP961890A (es) Benzotiofenos lipofilos (caso x- 10395)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application